Alyeska Investment Group
NBIX icon

Alyeska Investment Group’s Neurocrine Biosciences NBIX Stock Holding History

Alyeska Investment Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$3.77M – 678
2025
Q2 		$3.77M Sell
30,000
-176,368
-85% -$20.2M 0.01% 443
2025
Q1 		$22.8M Sell
206,368
-42,560
-17% -$5.39M 0.09% 229
2024
Q4 		$34M Buy
+248,928
New +$30.8M 0.13% 194
2024
Q3 		– Sell
-40,000
Closed -$5.51M – 640
2024
Q2 		$5.51M Buy
+40,000
New +$5.49M 0.03% 325
2019
Q1 		– Sell
-40,000
Closed -$2.86M – 426
2018
Q4 		$2.86M Buy
+40,000
New +$3.83M 0.04% 264
2017
Q3 		– Sell
-21,280
Closed -$979K – 511
2017
Q2 		$979K Sell
21,280
-11,612
-35% -$563K 0.01% 412
2017
Q1 		$1.42M Sell
32,892
-612,644
-95% -$26.2M 0.01% 417
2016
Q4 		$25M Buy
645,536
+204,301
+46% +$9.25M 0.21% 173
2016
Q3 		$22.3M Sell
441,235
-19,897
-4% -$991K 0.21% 163
2016
Q2 		$21M Buy
461,132
+119,439
+35% +$5.5M 0.2% 178
2016
Q1 		$13.5M Buy
341,693
+51,725
+18% +$2.05M 0.12% 217
2015
Q4 		$16.4M Buy
+289,968
New +$14.7M 0.17% 173

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alyeska Investment Group's NBIX Position: Q3 2025 in Review

Alyeska Investment Group sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 30,000 shares — an estimated $3.77M sold.

Alyeska Investment Group first reported a position in NBIX in Q4 2015 and held it in 12 quarters. The position peaked at $34M in Q4 2024. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Alyeska Investment Group reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 30,000 Neurocrine Biosciences shares in Q3 2025, an estimated $3.77M.
  • Alyeska Investment Group first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 12 quarters.
  • Alyeska Investment Group's Neurocrine Biosciences position peaked at $34M in Q4 2024.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.